AbbVie Inc. (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab‑A; ABBV‑400), an investigational next‑generation c‑Met‑directed antibody‑drug conjugate (ADC), in two solid‑tumor indications: refractory metastatic colorectal cancer (CRC) and locally advanced or metastatic non‑small cell lung cancer (NSCLC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Designation Type | Breakthrough Therapy Designation (×2) |
| Product | Temab‑A (telisotuzumab adizutecan; ABBV‑400) |
| Indication 1 | In combination with bevacizumab for adults with refractory, metastatic CRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, anti‑VEGF mAb, and (if indicated) anti‑EGFR mAb |
| Indication 2 | Monotherapy for adults with locally advanced or metastatic EGFR wild‑type, c‑Met‑expressing, non‑squamous NSCLC previously treated with platinum‑based chemotherapy and anti‑PD‑(L)1 antibody |
| Announcement Date | 7 Oct 2026 |
| Supporting Evidence | First‑in‑human Study M21‑404 (NCT05029882) |
Drug Profile & Mechanism of Action
- Molecule: Investigational next‑generation antibody‑drug conjugate (ADC)
- Target: c‑Met (hepatocyte growth factor receptor), a receptor tyrosine kinase frequently overexpressed or dysregulated in CRC and NSCLC, associated with poor prognosis and therapeutic resistance
- Payload: Novel topoisomerase‑1 inhibitor (Top1i) cytotoxic warhead, designed to maximize tumor‑cell killing upon internalization while limiting off‑target toxicity
- Innovation: Combines a highly specific c‑Met‑directed antibody with a next‑generation Top1i payload, positioning Temab‑A as a differentiated ADC in a rapidly evolving therapeutic class
- Development Stage: First‑in‑human; Phase I/II dose‑escalation and expansion (Study M21‑404)
Clinical Evidence – First‑in‑Human Study M21‑404
| Endpoint | Detail |
|---|---|
| Trial Identifier | NCT05029882 |
| Phase | Phase I/II (first‑in‑human) |
| Population | Patients with advanced solid tumors expressing c‑Met |
| Primary Endpoint | Safety and tolerability (dose‑escalation); preliminary efficacy (expansion) |
| Key Results | Data supporting BTD applications; specific efficacy endpoints Not disclosed in press release |
The M21‑404 study is an open‑label, multicenter trial evaluating Temab‑A as monotherapy and in combination regimens across multiple solid‑tumor types. The FDA’s decision to grant BTDs in two distinct indications signals that the agency views the preliminary data as addressing significant unmet medical needs in heavily pretreated patient populations with limited therapeutic options.
Market Impact & Outlook
- Colorectal Cancer Landscape: Refractory metastatic CRC remains one of the most challenging gastrointestinal malignancies, with median overall survival measured in months after exhaustion of standard chemotherapy and targeted biologic options. A c‑Met‑directed ADC offers a novel mechanism of action orthogonal to existing anti‑VEGF and anti‑EGFR regimens.
- NSCLC Landscape: EGFR wild‑type, c‑Met‑expressing NSCLC patients who progress on platinum chemotherapy and immunotherapy represent a population with acute unmet need and no established standard of care beyond clinical trials.
- Competitive Positioning: Temab‑A’s c‑Met targeting + Top1i payload combination differentiates it from other ADCs in development that target HER2, TROP‑2, or HER3, potentially reducing competitive overlap.
- Strategic Significance: Dual BTDs in two major solid‑tumor indications signal AbbVie’s deepening commitment to oncology ADCs, complementing its established immunology and neuroscience franchises.
- Next Steps: Pivotal trial initiation timelines and registration strategy Not disclosed; BTD status grants rolling review eligibility and intensive FDA engagement, potentially accelerating development timelines.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory trajectory, and commercial potential of Temab‑A. Breakthrough Therapy Designation does not guarantee accelerated approval or marketing authorization. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, competitive dynamics, and the inherent uncertainties of drug development.-Fineline Info & Tech
